INDV Logo

Indivior PLC - Ordinary Shares (INDV) Stock Forecast & Price Prediction

Live INDV Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic

$11.40

-0.33 (-2.81%)

12 Month Price Forecast For INDV

$11.40
Current Price
$1.41B
Market Cap
7 Ratings
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to INDV Price Forecasts

+40.4%
To High Target of $16.00
+40.4%
To Median Target of $16.00
+40.4%
To Low Target of $16.00

INDV Price Momentum

-6.6%
1 Week Change
-4.8%
1 Month Change
-37.6%
1 Year Change
-8.3%
Year-to-Date Change
-50.9%
From 52W High of $23.22
+55.5%
From 52W Low of $7.33

๐Ÿค” Considering Indivior (INDV)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 1:57 AM UTC

INDV Analyst Ratings & Price Targets

Based on our analysis of 2 Wall Street analysts, INDV has a consensus that is bullish. The median price target is $16.00, with forecasts ranging from $16.00 to $16.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With INDV currently trading at $11.40, the median price forecast suggests a 40.4% upside. The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 40.4% upside, while David Amsellem at Piper Sandler provides the most conservative target, suggesting a 40.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

INDV Analyst Consensus

7
Buy
0
Hold
0
Sell

INDV Price Target Range

Low
$16.00
Average
$16.00
High
$16.00
Current: $11.40

Latest INDV Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for INDV.

Date Firm Analyst Rating Change Price Target
Oct 25, 2024 Piper Sandler David Amsellem Overweight Reiterates $16.00
Oct 11, 2024 Craig-Hallum Chase Knickerbocker Buy Maintains $16.00
Oct 11, 2024 Piper Sandler David Amsellem Overweight Reiterates $15.00
Sep 13, 2024 Piper Sandler David Amsellem Overweight Reiterates $22.00
Jul 23, 2024 Piper Sandler David Amsellem Overweight Initiates $22.00
Jul 10, 2024 Craig-Hallum Chase Knickerbocker Buy Maintains $24.00
Apr 3, 2024 Craig-Hallum Chase Knickerbocker Buy Initiates $37.00

Stocks Similar to Indivior PLC - Ordinary Shares

The following stocks are similar to Indivior based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Indivior PLC - Ordinary Shares (INDV) Financial Data

Indivior PLC - Ordinary Shares has a market capitalization of $1.41B with a P/E ratio of 272.0x. The company generates $1.18B in trailing twelve-month revenue with a -0.3% profit margin.

Revenue growth is +13.3% quarter-over-quarter, while maintaining an operating margin of +30.6% and return on equity of N/A.

Valuation Metrics

Market Cap $1.41B
Enterprise Value $1.44B
P/E Ratio 272.0x
PEG Ratio 10.3x
Price/Sales 1.2x

Growth & Margins

Revenue Growth (YoY) +13.3%
Gross Margin +77.5%
Operating Margin +30.6%
Net Margin -0.3%
EPS Growth +13.3%

Financial Health

Cash/Price Ratio +21.5%
Current Ratio 0.8x
Debt/Equity -1.7x
ROE N/A
ROA +11.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Indivior PLC - Ordinary Shares logo

Indivior PLC - Ordinary Shares (INDV) Company Overview

About Indivior PLC - Ordinary Shares

What They Do

Develops drugs for opioid dependence treatment.

Business Model

The company generates revenue by developing, manufacturing, and selling prescription medications primarily focused on treating opioid dependence and related disorders. Its core products, including SUBLOCADE and SUBOXONE, are marketed in the United States and internationally, contributing to its earnings through direct sales and partnerships for ongoing drug development.

Additional Information

Indivior PLC is actively engaged in research and development of new treatments, including several drugs currently in various clinical trial phases. The company collaborates with other organizations for the advancement of its products, indicating a strong commitment to innovation in the treatment of substance use disorders. Established in 2014 and based in Virginia, Indivior is positioned in a critical healthcare sector addressing significant public health challenges.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1,000

CEO

Mr. Mark Crossley

Country

United States

IPO Year

2014

Indivior PLC - Ordinary Shares (INDV) Latest News & Analysis

INDV stock latest news image
Quick Summary

A study indicates that once-monthly SUBLOCADE enhances retention in opioid use disorder patients, particularly those with fentanyl. A second injection was given a week later for quicker medication levels.

Why It Matters

Improved retention rates and faster medication levels for OUD patients with SUBLOCADE could enhance market share and revenue for the product, signaling potential growth for the pharmaceutical company involved.

Source: PRNewsWire
Market Sentiment: Neutral
INDV stock latest news image
Quick Summary

Indivior PLC is considering proposals from Oaktree Capital Management for enhancing shareholder value while maintaining its current strategy. The company emphasizes engagement with the investor.

Why It Matters

Indivior's openness to Oaktree's proposals signals potential changes in governance and strategy, which could impact shareholder value and stock performance.

Source: Proactive Investors
Market Sentiment: Neutral
INDV stock latest news image
Quick Summary

Indivior PLC's Board acknowledged receipt of a letter from Oaktree Capital Management on November 7, 2024.

Why It Matters

Oaktree's letter to Indivior's Board may signal potential strategic changes or influence, impacting stock performance and investor sentiment.

Source: PRNewsWire
Market Sentiment: Neutral
INDV stock latest news image
Quick Summary

Indivior PLC highlighted the effectiveness and safety of SUBLOCADEยฎ for opioid use disorder treatment, emphasizing its role in improving outcomes like abstinence and recovery during Substance Abuse Prevention Month.

Why It Matters

Positive data on SUBLOCADE's effectiveness in treating opioid use disorder can boost Indivior's market position and investor confidence, potentially leading to increased sales and stock performance.

Source: PRNewsWire
Market Sentiment: Neutral
INDV stock latest news image
Quick Summary

Indivior PLC maintains its full-year outlook despite a recent profit warning. The company faces short-term challenges but aims to reassure investors amid rising competition.

Why It Matters

Indivior's steady outlook amidst recent profit warnings signals mixed confidence, impacting market perceptions of its resilience against competition and future performance.

Source: Proactive Investors
Market Sentiment: Neutral
INDV stock latest news image
Quick Summary

Indivior PLC's share price rose 11% after reaffirming its full-year outlook. Q3 revenue increased 13% to $307M, with Sublocade sales up 14% to $191M.

Why It Matters

Indivior's 11% share price jump signals investor confidence after strong Q3 results and reaffirmed guidance, despite competitive pressures on Sublocade, indicating potential growth resilience.

Source: Proactive Investors
Market Sentiment: Positive

Frequently Asked Questions About INDV Stock

What is Indivior PLC - Ordinary Shares's (INDV) stock forecast for 2025?

Based on our analysis of 2 Wall Street analysts, Indivior PLC - Ordinary Shares (INDV) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $16.00.

Is INDV stock a good investment in 2025?

According to current analyst ratings, INDV has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.40. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for INDV stock?

Wall Street analysts predict INDV stock could reach $16.00 in the next 12 months. This represents a 40.4% increase from the current price of $11.40. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Indivior PLC - Ordinary Shares's business model?

The company generates revenue by developing, manufacturing, and selling prescription medications primarily focused on treating opioid dependence and related disorders. Its core products, including SUBLOCADE and SUBOXONE, are marketed in the United States and internationally, contributing to its earnings through direct sales and partnerships for ongoing drug development.

What is the highest forecasted price for INDV Indivior PLC - Ordinary Shares?

The highest price target for INDV is $16.00 from David Amsellem at Piper Sandler, which represents a 40.4% increase from the current price of $11.40.

What is the lowest forecasted price for INDV Indivior PLC - Ordinary Shares?

The lowest price target for INDV is $16.00 from David Amsellem at Piper Sandler, which represents a 40.4% increase from the current price of $11.40.

What is the overall INDV consensus from analysts for Indivior PLC - Ordinary Shares?

The overall analyst consensus for INDV is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.

How accurate are INDV stock price projections?

Stock price projections, including those for Indivior PLC - Ordinary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.